Terms: = Gastric cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
26 results:
1. Predictive Value of a New Muscle Parameter in Patients with Resectable gastric cancer: A Pooled Analysis of Three Prospective Trials.
Zhong Q; Huang JB; Lu J; Xue LW; Lin GT; Xie JW; Lin JX; Zheng CH; Huang CM; Li P
Ann Surg Oncol; 2024 May; 31(5):3005-3016. PubMed ID: 38270825
[TBL] [Abstract] [Full Text] [Related]
2. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
[TBL] [Abstract] [Full Text] [Related]
3. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience.
Tastekin D; Paksoy N; Dogan I; Ferhatoglu F; Khanmammadov N; Bozbey HU; Karabulut S
J Cancer Res Ther; 2023; 19(2):253-258. PubMed ID: 37006064
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers.
Hu M; Li Y; Li J; Zhou H; Liu C; Liu Z; Gong Y; Ying B; Xie Y
Eur J Med Chem; 2022 Dec; 244():114775. PubMed ID: 36208507
[TBL] [Abstract] [Full Text] [Related]
5. Expressions of Putative cancer Stem Cell Markers, CD44 and CD133, are Correlated with Pathological Tumour Stage in gastric Adenocarcinoma.
Duzcu SE; Astarci HM; Tunc N; Boran C
J Coll Physicians Surg Pak; 2021 May; 31(5):553-558. PubMed ID: 34027868
[TBL] [Abstract] [Full Text] [Related]
6. Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.
Lu J; Xu BB; Xue Z; Xie JW; Zheng CH; Huang CM; Li P
Cancer Med; 2021 Jan; 10(1):34-44. PubMed ID: 33270989
[TBL] [Abstract] [Full Text] [Related]
7. Intra-tumor metabolic heterogeneity of gastric cancer on
Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
[TBL] [Abstract] [Full Text] [Related]
8.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
9. Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent gastric cancer after Curative Resection.
Kim SH; Song BI; Kim HW; Won KS; Son YG; Ryu SW
Korean J Radiol; 2020 Jul; 21(7):829-837. PubMed ID: 32524783
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study.
Kurokawa Y; Yamashita K; Kawabata R; Fujita J; Imamura H; Takeno A; Takahashi T; Yamasaki M; Eguchi H; Doki Y
Gastric Cancer; 2020 Sep; 23(5):937-943. PubMed ID: 32314097
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract] [Full Text] [Related]
12. Multiparametric MRI and
Yoo J; Kim SH; Han JK
Eur Radiol; 2020 Mar; 30(3):1634-1643. PubMed ID: 31781931
[TBL] [Abstract] [Full Text] [Related]
13. Volumetric parameters on
Liu G; Hu Y; Cheng X; Wang Y; Gu Y; Liu T; Shi H
BMC Cancer; 2019 Aug; 19(1):790. PubMed ID: 31395059
[TBL] [Abstract] [Full Text] [Related]
14. Postoperative ratio of the maximum C-reactive protein level to the minimum peripheral lymphocyte count as a prognostic indicator for gastric cancer patients.
Kono Y; Saito H; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Yamamoto M; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
Surg Today; 2019 Mar; 49(3):206-213. PubMed ID: 30317493
[TBL] [Abstract] [Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract] [Full Text] [Related]
16. Poor performance in incremental shuttle walk and cardiopulmonary exercise testing predicts poor overall survival for patients undergoing esophago-gastric resection.
Whibley J; Peters CJ; Halliday LJ; Chaudry AM; Allum WH
Eur J Surg Oncol; 2018 May; 44(5):594-599. PubMed ID: 29459017
[TBL] [Abstract] [Full Text] [Related]
17. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract] [Full Text] [Related]
18. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced gastric cancer Undergoing Chemotherapy: Association and Clinical Implication.
Park S; Ha S; Kwon HW; Kim WH; Kim TY; Oh DY; Cheon GJ; Bang YJ
J Nucl Med; 2017 Jun; 58(6):899-904. PubMed ID: 28572288
[TBL] [Abstract] [Full Text] [Related]
19. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract] [Full Text] [Related]
20. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.
He D; Zhang YW; Zhang NN; Zhou L; Chen JN; Jiang Y; Shao CK
Med Oncol; 2015 Apr; 32(4):92. PubMed ID: 25720522
[TBL] [Abstract] [Full Text] [Related]
[Next]
